Showing results (31-40 of 59) with videos related to
Sort By:
Pageof 6
AIDS (London, England)|January 10, 2014
Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartmentsSlim Fourati, Sidonie Lambert-Niclot, Cathia Soulie, et al.The Journal of Antimicrobial Chemotherapy|June 13, 2012
HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirsSlim Fourati, Sidonie Lambert-Niclot, Cathia Soulie, et al.The Journal of Antimicrobial Chemotherapy|May 27, 2014
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytesMichela Pollicita, Matteo Surdo, Fabiola Di Santo, et al.Life (Basel, Switzerland)|December 23, 2022
SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization TestStephane Marot, Djeneba Bocar Fofana, Philippe Flandre, et al.Antimicrobial Agents and Chemotherapy|January 30, 2008
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroIsabelle Malet, Olivier Delelis, Marc-Antoine Valantin, et al.Journal of Virology|June 27, 2022
Mutations in the 3'-PPT Lead to HIV-1 Replication without IntegrationClémence Richetta, Frédéric Subra, Isabelle Malet, et al.European Journal of Neurology|June 13, 2023
Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralizationCéline Louapre, Lisa Belin, Stéphane Marot, et al.The Journal of Antimicrobial Chemotherapy|April 9, 2014
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitorsIsabelle Malet, Laura Gimferrer Arriaga, Anna Artese, et al.The Journal of Antimicrobial Chemotherapy|July 6, 2012
Risk factors for raltegravir resistance development in clinical practiceIsabelle Malet, Slim Fourati, Laurence Morand-Joubert, et al.The Journal of Antimicrobial Chemotherapy|July 23, 2013
Highly multidrug-resistant HIV: clonal analysis and therapeutic strategiesEve Todesco, Sophie Sayon, Slim Fourati, et al.Pageof 6